selexipag

Drug Overview

Selexipag is a breakthrough pharmaceutical intervention within the specialized Pulmonology Drug Category, specifically developed to address the complex vascular challenges of the lungs. It is a first-in-class member of the Prostacyclin Receptor Agonist Drug Class. Unlike standard medications that focus on the airways, selexipag targets the pulmonary circulatory system to alleviate the high-pressure environment that leads to chronic respiratory failure and right-sided heart strain.

This guide provides international patients and healthcare professionals with a trustworthy, academic, yet accessible overview of managing severe pulmonary vascular disorders with modern oral therapy.

• Generic Name / Active Ingredient: Selexipag.
• US Brand Names: Uptravi.
• Route of Administration: Oral (Tablets) and Intravenous (IV) infusion (for temporary use).
• FDA Approval Status: Fully FDA-approved for the treatment of Pulmonary Arterial Hypertension (PAH) to delay disease progression and reduce the risk of hospitalization.
  
  Find essential patient information on selexipag for pulmonary arterial hypertension. Explore our hospital’s resources on dosage and expert cardiac care.

What Is It and How Does It Work? (Mechanism of Action)

Selexipag is an orally active, selective IP prostacyclin receptor agonist. It is designed to mimic the effects of prostacyclin, a naturally occurring substance in the body that keeps blood vessels relaxed and open.

At the molecular and physiological level, selexipag is a “prodrug.” After ingestion, it is metabolized by the liver into its active form, which has a much higher affinity for the prostacyclin (IP) receptor. When the active metabolite binds to IP receptors on the smooth muscle cells lining the pulmonary arteries, it stimulates the enzyme adenylate cyclase. This stimulation increases the intracellular levels of cyclic adenosine monophosphate (cAMP).

Increased cAMP levels lead to a significant decrease in intracellular calcium, which forces the smooth muscles surrounding the pulmonary blood vessels to relax. This physiological relaxation results in profound vasodilation (widening) of the pulmonary vascular bed. By widening these high-pressure vessels, selexipag lowers pulmonary vascular resistance, making it much easier for the right side of the heart to pump blood through the lungs to receive oxygen. Unlike older prostacyclin therapies, selexipag is highly selective for the IP receptor, which helps provide vascular relief while minimizing some of the systemic side effects associated with non-selective agents.

FDA-Approved Clinical Indications

Selexipag is utilized as a foundational TARGETED THERAPY to manage the long-term stability of patients with pulmonary vascular disease.

• Primary Indication: Treatment of Pulmonary Arterial Hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization.
• Other Approved & Off-Label Uses: Transition therapy for patients temporarily unable to take oral medication (IV formulation). It is not indicated for the treatment of standard Asthma, COPD, or Cystic Fibrosis.

Primary Pulmonology Indications:

• Improvement of Ventilation-Perfusion (V/Q) Matching: By dilating constricted pulmonary arteries, it ensures that blood flow reaches the oxygen-rich areas of the lungs more efficiently.
• Reduction in Hospitalization Rates: Clinical use is specifically geared toward preventing the acute cardiovascular “crashes” associated with PAH.
• Slowing Vascular Remodeling: Consistent receptor activation helps prevent the permanent thickening and scarring of the lung’s blood vessels, preserving long-term heart and lung function.

Dosage and Administration Protocols

Selexipag utilizes a “titration” schedule. This means patients start at a very low dose, which is gradually increased over several weeks to find the highest dose the individual can tolerate comfortably.

Administration Instructions: Tablets should be swallowed whole with water, preferably with food to improve tolerability. Unlike an INHALED CORTICOSTEROID (ICS), there is no need to rinse the mouth. If a dose is missed, it should be taken as soon as possible unless the next dose is within 6 hours.

Dose Adjustments:

For patients with moderate hepatic (liver) impairment, once-daily dosing is recommended. Use is avoided in severe hepatic impairment. There are no specific adjustments for elderly patients or those with renal issues, though close monitoring is required. Accuracy is critical: this is a long-acting vascular TARGETED THERAPY, not a Short-Acting (SABA) rescue medication.

Warning: Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data from the 2020-2026 period reinforces selexipag’s role in the “triple therapy” approach to PAH. In the landmark GRIPHON study, one of the largest trials in PAH history, selexipag demonstrated precise numerical improvements in patient outcomes.

Research data showed that selexipag reduced the risk of a primary composite endpoint (death or a complication related to PAH) by 40% compared to a placebo. While FEV¹ is not the primary metric for vascular lung disease, efficacy is measured by the 6-minute walk distance (6MWD). Clinical trials showed that patients on selexipag maintained or improved their 6MWD by an average of 12 meters over long-term follow-up, compared to a decline in the placebo group.

Furthermore, selexipag is efficacious in improving the overall quality of life by reducing the symptoms of shortness of breath and fatigue. Backup research data confirms that when added to other TARGETED THERAPY agents (like ERA or PDE5 inhibitors), selexipag provides a synergistic effect that significantly lowers pulmonary arterial pressure and improves the heart’s pumping efficiency.

Safety Profile and Side Effects

Black Box Warning: There is no Black Box Warning for selexipag.

However, because the medication dilates blood vessels systemically as well as in the lungs, certain side effects are common during the titration phase:

• Common Side Effects (>10%): Headache, diarrhea, jaw pain, nausea, myalgia (muscle pain), and flushing.
• Serious Adverse Events: Anemia (decreased red blood cells), pulmonary edema in patients with pulmonary veno-occlusive disease, and hyperthyroidism.

Management Strategies: Most side effects like jaw pain and headache are most intense during the dose-increase phase and often improve over time. Clinicians may recommend over-the-counter pain relievers or anti-diarrheal medications to manage these symptoms during titration. Unlike a BRONCHODILATOR, heart rate monitoring is not the primary focus, but blood pressure should be monitored regularly.

Research Areas

Direct Clinical Connections in recent research (2020-2026) focus on selexipag’s impact on airway remodeling and right-ventricular strain. Studies are evaluating whether long-term IP receptor agonism can physically “reverse” the thickening of vessel walls.

Generalization and advancements include active clinical trials regarding “Upfront Triple Therapy.” Instead of waiting for a patient to worsen, researchers are testing if starting selexipag immediately alongside two other classes of PAH drugs can stop end-stage lung disease before it starts.

In the realm of Severe Disease & Precision Medicine, research into BIOLOGIC phenotyping is helping identify which PAH patients have the specific receptor sensitivity to respond best to selexipag. This ensures the drug is used as a highly specific TARGETED THERAPY for those who will benefit most, preventing the progression toward lung transplantation.

Disclaimer: Information in this section regarding the potential for physically “reversing” the thickening of vessel walls and the use of biologic phenotyping to identify receptor sensitivity is considered investigational. While these concepts are at the forefront of pulmonary research in 2026, they are not yet established as standardized clinical indications or definitive outcomes for this medication.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A Right Heart Catheterization is mandatory to confirm the PAH diagnosis and measure baseline vascular resistance. Baseline Spirometry (PFTs) and Chest X-ray help rule out other obstructive airway diseases.
• Organ Function: Baseline hepatic monitoring is essential, as the drug is activated by liver enzymes.
• Specialized Testing: Pulse Oximetry (SpO₂) and 6-minute walk distance (6MWD) to establish baseline functional status.
• Screening: Review of current medications and tobacco use history.

Monitoring and Precautions

• Vigilance: Monitoring for “Step-up” needs. If the patient’s functional class does not improve, additional therapies may be added.
• Lifestyle: Smoking cessation is an absolute requirement, as smoke further constricts lung vessels. Patients must avoid high altitudes and follow a low-sodium diet to protect the heart.
• Vaccination: Maintenance of Flu and Pneumonia vaccinations is critical to prevent infections that could overwhelm the pulmonary circulation.

Do’s and Don’ts

• DO take the medication with food to help reduce stomach upset and jaw pain.
• DO keep a detailed log of your symptoms during the titration phase to help your doctor find your “optimal” dose.
• DON’T stop the medication suddenly, as this can cause a dangerous rebound increase in lung blood pressure.
• DON’T swallow tablets with grapefruit juice, as it can interfere with the liver’s ability to process the drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis, treatment, or clinical guidance. Always seek the advice of your physician, pulmonologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, chronic respiratory failure, or Pulmonary Arterial Hypertension. Never disregard professional medical advice or delay in seeking it because of something you have read in this material. Dosage and treatment plans must always be individualized by a licensed medical professional.